Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference
Comparison of High-Dose Bolus
Tirofiban With Other Anticoagulants in 41 Clinical Studies Involving 38,645
Patients Selected as iMPACT Trial
WINNIPEG., Medicure Inc. ("Medicure" or the "Company"), a specialty pharmaceutical company, today announced that a study titled "Comparison of High-Dose Bolus Tirofiban With Other Anticoagulation Strategies for Percutaneous Coronary Intervention: A Network Meta-Analysis of Randomized Controlled Trials"was presented by primary investigator and lead author, Dr. Michael J. Lipinski, M.D., Ph.D., of the MedStar Heart and Vascular Institute in Washington, DC at the Cardiovascular Research Technologies (CRT) 2016 conference.
The CRT conference, which concludes today at the Omni Shoreham Hotel in Washington, DC, is one of the leading educational forums on new cardiovascular technology and procedures for physicians and health care professionals.
The study was selected as a late-breaking iMPACT Trial at the CRT conference. iMPACT Trials are those studies selected to be innovative and providing the latest breakthroughs in clinical science, and are expected to highlight new improvements in quality of patient care and significantly "iMPACT" the field of interventional cardiology.
The investigators pooled data from 41 randomized clinical trials to perform a network meta-analysis to directly and indirectly compare different glycoprotein IIb/IIIa inhibitor (GPI) strategies for percutaneous coronary intervention with a focus on the impact of High-Dose Bolus (HDB) tirofiban. A total of 38,645 patients were included in the analysis (2,654 randomized to HDB tirofiban, 6,752 to abciximab, 1,669 to eptifibatide, 16,500 to heparin, and 11,070 to bivalirudin). Results of the analysis found that HDB tirofiban had a significant reduction in all-cause mortality when compared with both heparin and eptifibatide (Integrilin®, Merck & Co., Inc.) (p<0.05). There was no significant difference among the GPI therapies for other outcomes including MI, MACE, and major bleeding.
For complete information, the study abstract can be accessed on the JACC Cardiovascular Interventions website athttp://interventions.onlinejacc.org/article.aspx?articleid=2492247.
This meta-analysis does not imply comparable efficacy, safety or product interchangeability. Some of the patient populations were outside of the approved patient populations for AGGRASTAT. Refer to U.S. Prescribing Information for complete product information.
Source: Medicure Inc.
Comments